UniSuper Management Pty Ltd Raises Position in Cencora, Inc. $COR

UniSuper Management Pty Ltd lifted its holdings in Cencora, Inc. (NYSE:COR) by 29.6% in the third quarter, Holdings Channel reports. The firm owned 18,696 shares of the company’s stock after buying an additional 4,269 shares during the period. UniSuper Management Pty Ltd’s holdings in Cencora were worth $5,843,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the business. Cornerstone Wealth Group LLC boosted its holdings in Cencora by 1.3% in the third quarter. Cornerstone Wealth Group LLC now owns 2,383 shares of the company’s stock worth $745,000 after acquiring an additional 30 shares in the last quarter. Security Financial Services INC. increased its holdings in shares of Cencora by 2.6% during the third quarter. Security Financial Services INC. now owns 1,325 shares of the company’s stock valued at $414,000 after acquiring an additional 33 shares in the last quarter. Atlantic Edge Private Wealth Management LLC increased its holdings in shares of Cencora by 70.0% during the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after acquiring an additional 35 shares in the last quarter. Hemington Wealth Management raised its position in shares of Cencora by 12.0% in the 3rd quarter. Hemington Wealth Management now owns 327 shares of the company’s stock valued at $102,000 after purchasing an additional 35 shares during the last quarter. Finally, Quadcap Wealth Management LLC boosted its stake in Cencora by 1.5% in the 2nd quarter. Quadcap Wealth Management LLC now owns 2,409 shares of the company’s stock worth $722,000 after purchasing an additional 36 shares in the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have weighed in on the stock. UBS Group boosted their target price on shares of Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Weiss Ratings reissued a “hold (c+)” rating on shares of Cencora in a report on Monday, December 29th. Evercore ISI set a $400.00 target price on Cencora and gave the stock an “outperform” rating in a research note on Thursday, November 6th. TD Cowen lifted their price target on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Finally, Mizuho boosted their price target on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $393.08.

Cencora Trading Up 0.2%

NYSE COR opened at $353.07 on Monday. The company has a market capitalization of $68.49 billion, a PE ratio of 44.41, a P/E/G ratio of 1.68 and a beta of 0.66. The company has a fifty day moving average of $348.49 and a 200 day moving average of $322.22. Cencora, Inc. has a 1 year low of $237.71 and a 1 year high of $377.54. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.05. The company had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period last year, the firm earned $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.7%. This is a positive change from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend was Friday, November 14th. Cencora’s dividend payout ratio is 30.19%.

Insider Buying and Selling

In other Cencora news, EVP Silvana Battaglia sold 1,677 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the sale, the executive vice president owned 18,796 shares in the company, valued at approximately $6,484,620. This represents a 8.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the transaction, the chief executive officer directly owned 66,726 shares of the company’s stock, valued at approximately $23,669,713.98. This trade represents a 7.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 20,316 shares of company stock valued at $7,151,265 over the last ninety days. Company insiders own 0.38% of the company’s stock.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.